288 related articles for article (PubMed ID: 31910836)
1. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.
Hung YC; Chiu LT; Huang HY; Bau DT
Cardiovasc Diabetol; 2020 Jun; 19(1):94. PubMed ID: 32563247
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study.
Liu CH; Sung PS; Li YR; Huang WK; Lee TW; Huang CC; Lee TH; Chen TH; Wei YC
PLoS Med; 2021 Jul; 18(7):e1003707. PubMed ID: 34280191
[TBL] [Abstract][Full Text] [Related]
4. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
Woo MH; Lee HS; Kim J
Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.
Ha J; Choi DW; Kim KY; Nam CM; Kim E
Cardiovasc Diabetol; 2021 Jul; 20(1):152. PubMed ID: 34315501
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Pai PY; Muo CH; Sung FC; Ho HC; Lee YT
Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172
[TBL] [Abstract][Full Text] [Related]
8. Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis.
Morgan CL; Inzucchi SE; Puelles J; Jenkins-Jones S; Currie CJ
Diabetes Obes Metab; 2018 Sep; 20(9):2140-2147. PubMed ID: 29732718
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Recurrent Ischemic Stroke in Obese Patients With Type 2 Diabetes Mellitus: A Population-based Study.
Albitar O; Harun SN; Abidin NE; Tangiisuran B; Zainal H; Looi I; Ibrahim KA; Sidek NN; Loo KW; Lee KY; Aziz ZA; Ghadzi SMS
J Stroke Cerebrovasc Dis; 2020 Oct; 29(10):105173. PubMed ID: 32912507
[TBL] [Abstract][Full Text] [Related]
10. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
11. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
Young LH; Viscoli CM; Schwartz GG; Inzucchi SE; Curtis JP; Gorman MJ; Furie KL; Conwit R; Spatz ES; Lovejoy A; Abbott JD; Jacoby DL; Kolansky DM; Ling FS; Pfau SE; Kernan WN;
Circulation; 2018 Sep; 138(12):1210-1220. PubMed ID: 29934374
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
Wang JL; Dong YH; Ko WC; Chang CH; Wu LC; Chuang LM; Chen PC
Diabetes Obes Metab; 2018 Dec; 20(12):2811-2820. PubMed ID: 29974616
[TBL] [Abstract][Full Text] [Related]
13. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
[TBL] [Abstract][Full Text] [Related]
14. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.
Nesti L; Tricò D; Mengozzi A; Natali A
Cardiovasc Diabetol; 2021 May; 20(1):109. PubMed ID: 34006325
[TBL] [Abstract][Full Text] [Related]
15. Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study.
Tanaka R; Yamashiro K; Okuma Y; Shimura H; Nakamura S; Ueno Y; Tanaka Y; Miyamoto N; Tomizawa Y; Nakahara T; Furukawa Y; Watada H; Kawamori R; Hattori N; Urabe T
J Atheroscler Thromb; 2015; 22(12):1305-16. PubMed ID: 26269002
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone on the incidence of dementia in patients with diabetes.
Chou PS; Ho BL; Yang YH
J Diabetes Complications; 2017 Jun; 31(6):1053-1057. PubMed ID: 28254448
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.
Li YR; Tsai SS; Chen DY; Chen ST; Sun JH; Chang HY; Liou MJ; Chen TH
Cardiovasc Diabetol; 2018 Jan; 17(1):2. PubMed ID: 29301579
[TBL] [Abstract][Full Text] [Related]
18. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
Yaghi S; Furie KL; Viscoli CM; Kamel H; Gorman M; Dearborn J; Young LH; Inzucchi SE; Lovejoy AM; Kasner SE; Conwit R; Kernan WN;
Circulation; 2018 Jan; 137(5):455-463. PubMed ID: 29084736
[TBL] [Abstract][Full Text] [Related]
20. Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment.
Zhou J; Xu B; He F; Shu Y; Chen X; Liu Z; Sun B; Zhang W
Cardiovasc Diabetol; 2024 May; 23(1):166. PubMed ID: 38730425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
